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Abstract
Epstein-Barr Virus (EBV) belongs to the gammaherpesvirus family, members of which are oncogenic. Compared
with other closely related herpesviruses, EBV has developed much more elaborate and sophisticated strategies for
subverting host immune system, which may account for its high prevalence in immune competent hosts. Thus,
study of EBV-specific immune dysregulation is important for understanding EBV latency and oncogenesis, and will
identify potential molecular targets for immunotherapeutic interventions. Here I summarize the recent findings of
individual EBV products in regulating host immune responses, with emphasis on the innate immune modulation.
Introduction
Epstein-Barr Virus (EBV), known as human herpesvirus
4 (HHV4), is the first identified human cancer virus that
has been shown to be associated with the development
of a wide spectrum of B-cell lymphoproliferative disor-
ders including Burkitt’s lymphoma (BL), Posttransplant
lymphoproliferative disorder (PTLD), and Hodgkin and
non-Hodgkin lymphomas, as well as epithelial cancers
including Nasopharyngeal carcinoma (NPC) and some
forms of gastric carcinoma [1]. EBV is also associated
with lymphomas occurring in rare patients with conge-
nital immunodeficiency such as X-linked lymphoproli-
ferative syndrome (XLP) [2], and plays a role in
lymphoproliferative disorders which most often occur in
immunocompromised patients with human immunode-
ficiency virus (HIV) infection (e.g. central nervous sys-
tem lymphoma) or after solid organ transplantation.
EBV, together with Kaposi’s sarcoma-associated herpes-
virus (KSHV/HHV8) and human papillomavirus (HPV),
are three oncogenic viruses causally involved in acquired
immune deficiency syndrome (AIDS)-associated malig-
nancies [3].
Herpesviruses are fascinating models for scientific
research as they establish lifelong persistent infections in
normal immunocompetent healthy hosts as well as are
able to be reactivated (replicate) for spreading to new
hosts. Human herpesviruses are of particularly medical
importance because they are associated with severe dis-
eases and cancers in immunocompromised hosts [4].
Among herpesviruses, EBV is a well-established para-
digm for the study of herpes viral infection, persistence,
and associated malignancies [4].
EBV infection and life cycle
EBV is spread by saliva contact, and then crosses muco-
sal epithelium in order to infect B cells in underlying
secondary lymphoid tissues like the tonsils and ade-
noids. Besides spread by saliva contact, EBV may be
sexually transmitted [5]. Breast milk of nursing mothers
may also contain EBV which could be from an uncom-
mon route of vertical transmission [6]. In healthy hosts,
the immune system forces invading EBV to enter the
destination “true latency” (latency 0) where the virus
hides inside the nucleus of lymphocytes without mani-
festing any symptoms. The virus in “true latency” is
neither pathogenic nor visible to the host immune sys-
tem due to the lack of any viral protein production. But
before the establishment of the final “true latency”,t h e
virus goes through several different “transitional” latency
programs, named latency 3, 2 and 1, which selectively
express several of the nine viral latent proteins as well
as noncoding RNAs (EBERs, BARF0, and miRNAs) and
are associated with EBV oncogenesis [4]. Persistent
latent infection is also characterized by stable numbers
of infected B cells in the blood and by the steady shed-
ding of infectious virus into saliva. The virus is continu-
ously surveilled by the host immune system in
persistent infection [7]. However, it is invisible to the
host immune system since these long-lived B cells are
quiescent and express fewer proteins, and do not
express any viral protein before their occasional division,
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cytotoxic T lymphocytes (CTLs), is expressed [8].
Besides latently infects lymphocytes and productively
infects epithelial cells, EBV also infects follicular dendri-
tic cells, mononuclear cells, plasma cells and smooth
muscle cells. Infection of monocytes is likely productive
[9]. However, in healthy carriers, EBV seems to be
exclusively harbored in B lymphocytes [6,7]. In vitro
infection of B cells leads to cell activation and prolifera-
tion, as well as outgrowth of transformed lymphoblas-
toid cell lines (LCLs, Latency 3).
Reactivation from latency in response to a specified
signal requires viral genomic DNA replication and the
synthesis of specific viral proteins for packing the newly
replicated DNA into infectious virions. Two immediate-
early (IE) transcription factors, BZLF1 and BRLF1, are
responsible for expression of these packing proteins.
EBV expresses a full repertoire of over 80 lytic proteins
during replication period. In healthy hosts, the replica-
tion program has to be transient, rapid, and relatively
rare to minimize the chances to be shut down by the
host immune system. On the other hand, the virus has
developed strategies to elude the immune response for
successful generation of viral progeny [4,7].
The host immune system plays pivotal roles in both
lytic and latent infections. It is currently deemed that a
delicate modulation between host immune system, tightly
controlled gene expression during distinct viral latency
programs, and limited replication, enables EBV to persist
in immunocompetent hosts without doing much harm
[7,10]. Thus, study of the interaction between the host
immune system and EBV is critical for understanding
how EBV controls the balance between immune
responses, undesired proliferation, and cell death, for its
oncogenic benefits, and will provide a basis for potential
immunotherapy for EBV-associated malignancies. Dysre-
gulation of EBV-specific immune responses is also char-
acteristic of EBV-associated autoimmune diseases such
as rheumatoid arthritis (RA) and systemic lupus erythe-
matosus (SLE). CTL response to EBV infection has been
well documented since the discovery of EBV [11]. How-
ever, significant progresses in characterizing individual
viral proteins involved in evasion of the T cell-mediated
adaptive immune response have only been made in the
last decade [12-16]. For example, the functional homolo-
gue of human IL10, BCRF1, elicits CD8
+ T cell responses,
and can be processed and presented to CD8
+ CTLs
through a TAP-independent pathway [17]. On the other
hand, how EBV regulates the host innate immune system
is much less understood, and only limited studies on this
important subject in EBV biology have been reported
recently. Here I summarize these findings which have
identified individual EBV products (including proteins,
noncoding RNAs, and EBV genomic DNA) involved in
regulating the host immune responses in both lytic and
latent infections, with focus on their roles in innate
immune modulation.
Elicitation of innate immune responses
In immunocompetent hosts, the attachment or entry of
herpesviruses elicits a vigorous CD8
+ Tc e l l - m e d i a t e d
adaptive immune response against infected cells [10]. In
the meantime, like other viruses, at the early stage of
infection, herpes viral infection mounts innate immune
responses in the host cell, significantly manifested by
activation of signaling pathways mediated by Toll-like
receptors (TLRs) [18-20].
GP350
Numerous studies with EBV GP350 (encoded by
BLLF1), the major envelope glycoprotein which med-
iates EBV entry into B cells through interaction with its
B-cell receptor CD21, have shown that acute and
chronic EBV infections in vitro result in changes in
secretion of TNF-a,I L - 1 b, IL-6, and IL-10 [21]. Like
other herpesviruses such as herpes simplex virus (HSV)
[22], varicella zoster virus (VZV) [19] and cytomegalo-
virus (CMV) [23], intact EBV virions can be recognized
by TLR2 in epithelial cells and monocytes, and this pro-
cess is likely mediated by GP350, suggesting that GP350
may act as a ligand for TLR2 [24] (Figure 1).
EBV dUTPase
In addition to the envelope protein GP350, the non-
structural protein dUTPase, which is encoded by the
gene BLLF3 and is one of the early antigens (EA), is
also a ligand recognized by TLR2 [25]. Recognition of
EBV dUTPase by TLR2 activates NFkappaB via a
MyD88-dependent signaling cascade, and induces
expression of proinflammatory cytokines in macro-
phages [25] (Figure 1). EBV LF1 (ORF10) and LF2
(ORF11) both contain a dUTPase-like domain. However,
LF2 dysregulation of host immune response may be
independent of its dUTPase-like domain [26].
EBERS
In latent infection, EBV constitutively encodes two non-
coding and nonpolyadenylated small nuclear RNAs,
EBV-encoded small nuclear RNA 1 (EBER1) and EBER2,
which form dsRNA-like stem-loop structure by intermo-
lecular base-pairing. EBERs have extensive structural
similarity to adenoviruses VA1 and VA2 as well as cellu-
lar U6 small RNAs. EBERs are transcribed by RNA poly-
merase III and therefore characterized by a 5’-
triphosphate moiety [27]. These features (dsRNA-like
structure and 5’-PPP) render EBERs capable to function
as ligands for the intracellular RNA receptor, Retinoic
acid-inducible gene I (RIG-I). Recognition of EBERs by
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induces interferons (IFNs), IFN-stimulated genes (ISGs)
[28], and the anti-inflammatory cytokine IL10 [29] (Fig-
ure 1). EBERs especially EBER1 can also be released by
secretion of the cellular partner, La (systemic lupus
erythematosus-associated antigen), from EBV-infected
cells and then lead to immune activation through recog-
nition by TLR3 and induce type I IFNs and inflamma-
tory cytokines [30] (Figure 1). In addition to RIG-I and
TLR3, EBERs also bind to IFN-inducible dsRNA-depen-
dent protein kinase (PKR), and inhibit PKR phosphory-
lation and mediated apoptosis [31] (Figure 1).
Type I IFNs and proinflammatory cytokines induced
by EBER1 are released from EBV-infected cells [30].
T h u s ,E B E R 1m a yp l a yar o l ei ni m m u n o p a t h o l o g i c
diseases associated with acute EBV infection such as
infectious mononucleosis (IM), chronic active EBV
infection, and EBV-associated hemophagocytic lympho-
histiocytosis, as well as in EBV-associated autoimmune
diseases such as SLE.
In addition to EBERs, EBV latency expresses a CG-
rich transcript, IR4, with dsRNA-like structure. IR4
induces type I IFNs through unclear mechanism [32].
EBV and TLR signaling
Interaction between viruses and TLR signaling plays a
pivotal role in virus-mediated innate immune elicitation
and evasion. As stated above, EBV GP350, dUTPase,
and EBERs can orchestrate TLR-mediated innate
immune responses. Furthermore, increasing evidence
has disclosed the interaction between EBV and TLR sig-
naling with distinct outcomes, depending on cell types.
In B lymphocytes, primary infection of EBV induces
expression of TLR7 and downregulates expression of
TLR9, as well as activates TLR7 signaling leading to
expression of the downstream target IRF5 and cell pro-
liferation [33] (Figure 1). Controversially, another study
has reported that primary infection of EBV impairs the
effect of TLR7/8/9 stimulation on B cell proliferation
[34]. In plasmacytoid dendritic cells, infection of EBV
Figure 1 Elicitation of innate immune response in EBV infection. EBV dUTPase and GP350 act as ligands for TLR2. EBV EBERs can mount
innate immune responses via both TLR3 and RIG-I signaling pathways. Infection of EBV also activates TLR9 signaling leading to IFNa production
in pDCs. In latency, EBV manipulates the TLR7/IRF5 signaling pathway, which promotes cell proliferation. EBV products are indicated in red fonts.
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duction, and promotes activation of NK cells and IFNg-
producing CD3+ T cells [35] (Figure 1). Since TLR9
recognizes CpG DNA motifs from bacterial or viral gen-
omes, presuming that EBV genomic DNA may service
as TLR9 ligand. In monocytes, both TLR9 and TLR2
contribute to immune responses elicited by EBV infec-
tion [24,36]. As such, the murid gammaherpesvirus 68
(MHV68), which is an animal model for study of human
gammaherpesviruses, also activates antiviral immune
responses in dendritic cells through TLR9 signaling
pathway [37]. However, primary infection of KSHV,
another gammaherpesvirus, results in TLR3-dependent
induction of proinflammatory chemokines and IFN,
most notably CXCL10 and IFNb in monocytes [38].
Interestingly, TLR7/8 stimulation also reactivates KSHV
from latency [38].
EBV and autoimmune diseases
EBV has been implicated in autoimmune diseases
including multiple sclerosis [39], RA [40] and SLE [41],
underscored by the fact that EBNA1 was initially identi-
fied as the target antigen of sera from RA patients [42].
EBNA1 is expressed in all types of latency as well as
lytic infection. Three fragments of EBNA1 protein,
including 398-PPPGMRPP-404, 35-GPAGPRGGGRGR-
GRGRGRGHNDGG-58, and 58-GGSGSGPRHRDG-
VRR-72 mimics the self-antigens Sm B/B’,S mD 1 ,a n d
Ro, respectively, and therefore EBNA1 is believed to
play a potential role in SLE [43]. Similarly, EBNA2
amino acids 354-GRGKGKSRDKQRKPGGPWRP-373
mimics Sm D1 antigen and may also contribute to SLE
[43].
In addition to EBNA1 and EBNA2, EBERs exist in a
snRNP complex containing La antigen specific to SLE
and Sjogren syndrome, and therefore are recognized
specifically by La antibody [44]. Given that recent stu-
dies showing the ability of EBER1 to provoke immune
responses [28,30,31], it is very intriguing to study if
EBER1 play a role in SLE in certain population.
Considering that TLRs, including TLR7, -8, and -9, are
also implicated in autoimmune diseases [45,46], these
TLRs may also contribute to EBV-associated autoim-
mune diseases, since EBV is able to regulate their
expression [33,34] and mayh a v es o m eo t h e ri n t e r a c -
tions with signaling pathways mediated by these TLRs.
Evasion of innate immune responses
Most viruses have evolved to encode strategies to elude
host immune responses for successful replication in the
host cell [47-53]. The fact that EBV infects and estab-
lishes life-long persistence in more than 95% of the
adult population indicates that it is very successful in
subverting host immune surveillance. In fact, EBV
encodes more ingenious tricks such as invoking the host
ubiquitination-proteasome system, compared with its
close member in the gamma herpes family, KSHV,
which encodes a larger volume of products for this pur-
pose. KSHV infects less than 2% of the general popula-
tion, indicating striking differences in their prevalence
and abilities to subvert host immune surveillance. Thus,
EBV has been a paradigm for studying host-virus inter-
actions. However, despite this fact and its medical
importance, EBV has been poorly understood in terms
of its evasion of host innate immunity. From limited
findings reported in recent years, three main strategies
can be identified for this purpose: (1) manipulating type
I and II IFN Jak-STAT signaling pathways; (2) regulating
expression and activity of IRFs; and (3) repressing apop-
tosis signaling pathways.
Immune evasion in latency
Limiting the number of expressed viral proteins and the
levels of each expressed viral protein are likely two main
strategies for EBV to escape the host immune system in
latency [13]. EBV only expresses limited proteins in
latency (9 in latency 3 and less in latency 1 and 2), and
both EBNA1 and EBNA3C have been shown to be able
to limit their own levels. In order to perform normal
latency functions with these limited proteins, EBV
encodes additional non-translated small RNAs (EBERs
and miRNAs), which can not be detected by T cells
looking for small peptides presented on MHC molecules
[13]. In addition, memory B cells, the potential site for
EBV long-term persistence [54], are not visible to
immune system [8].
EBNA1
EBV EBNA1 is the only EBV protein expressed in all
latency program and lytic cycle, and is essential for per-
sistence of EBV genome and establishment of latency in
the host cell. EBNA1 is a typical example that escapes
proteasomal processing, a process for the generation of
peptides for the MHC class I antigen presentation. The
long Gly-Ala repeats of EBNA1 are necessary for its
escape of proteasomal processing through possible inter-
ference with the recognition and unfolding functions of
the 19 S subunit [3,55] (Figure 2). The KSHV functional
homolog of EBNA1, latency-associated nuclear antigen
(LANA), also blocks proteasomal degradation and inhi-
bits MHC class I-mediated antigen presentation [56].
Furthermore, EBNA1 prevents its own synthesis to keep
at low but sustainable levels to avoid recognition by
CTL [57]. Paradoxically, EBNA1 contains 3 peptide frag-
ments which cross-react with three autoantigens and
therefore may contribute to development of autoim-
mune disorders SLE, RA and multiple sclerosis [43].
EBNA1 recruits the host CK2 kinase to phosphorylate
promyelocytic leukaemia nuclear protein (PML, also
Ning Herpesviridae 2011, 2:1
http://www.herpesviridae.org/content/2/1/1
Page 4 of 11known as TRIM19 and RNF71) nuclear bodies (PML-
NBs), and this phosphorylation leads to PML disruption
through the ubiquitination pathway mediated by the
ubiquitin-specific protease 7 (USP7, also known as her-
pesvirus-associated ubiquitin-specific protease (HAUSP))
in NPC cell lines [58,59] (Figure 2). PML is an ISG
which is a multiple functional protein with an important
role in antiviral responses [60].
Recent studies have shown that EBNA1, in addition to
EBNA3C and LMP1, promotes genomic instability and
Figure 2 Evasion of immune responses by individual EBV products. Individual EBV products, including proteins, miRNAs, and EBERs, are
shown to evade immune responses in both latent (upper) and lytic (lower) infections. For innate immune evasion, three main strategies are
employed: (1) manipulating type I and II IFN Jak-STAT pathway; (2) regulating expression and activity of IRFs, and (3) repressing apoptosis signaling.
EBV products are indicated in red fonts. PRD: positive regulatory domain; VRE: virus responsive element; ISRE: IFN-stimulated response element.
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response [61,62], and may facilitate c-myc translocation.
These findings argue that EBNA1 is a potential onco-
gene [63].
LMP1
Latent membrane protein 1 (LMP1) is accepted as the
principal EBV oncoprotein which promotes cell growth
and transformation in multiple cell backgrounds and in
transgenic mice. As a member of the tumor necrosis
factor receptor (TNFR) superfamily, LMP1 shares many
signaling intermediates with TLRs, and both LMP1 and
TLRs activate NFkappaB, a subset of IRFs, and AP1.
Furthermore, LMP1 is a pleiotropic factor with distinct
functions including metastasis, apoptotic resistance, and
immune modulation, which heavily depend on its
proper intracellular trafficking and the host cellular con-
t e x t[ 6 4 ] .I th a sb e e ns h o w nt h a ta tl e a s ti nh u m a n
embryonic kidney (HEK) cells, LMP1 principally signals
from intracellular compartments [65]. The immune
modulation function of LMP1 may associate with exo-
some which plays a role in antigen transfer. In fact,
LMP1 is enriched in exosomes isolated from EBV-posi-
tive B cells and epithelial cells, and may stimulate bio-
genesis and secretion of exosomes in these cells [64]. In
EBV-transformed B lymphocytes, a small portion of
LMP1 undergoes phosphorylation, and phosphorylated
LMP1 is preferentially associated with vimentin in the
cytoskeleton network [66].
LMP1 N-terminal transmembrane domain interacts
with Tyk2 and consequently, suppresses phosphorylation
of both STAT1 and -2 and subsequently blocks type I
IFN-mediated antiviral responses [67]. Paradoxically,
LMP1 has also been shown to stimulate tyrosine phos-
phorylation of STAT1 and induces its expression in
EBV-transformed B cells [68,69]. LMP1 was also shown
to have antiviral effect by inducing type I IFNs upon
superinfection through activation of NFkappaB and
IRF7 by its C-terminal activation regions (CTARs) [70]
and by inducing some ISGs such as STAT1, 2’,5’-oligoa-
denylate-synthetases (OAS) and ISG15 [71]. Further-
more, LMP1 induces a larger spectrum of genes involved
in immune regulation such as chemokines CCL17 and
CCL22, interleukins IL10, IL8 and IL6, and antigen pro-
cessing and presentation proteins MHC class I and II and
TAP2 (Figure 2). Moreover, LMP1 expressed at high
levels induces autophagy [72], a cellular process which
enhances antigen presentation to expose the infected
cells to immune system. Thus, LMP1 seems to have
opposite and diverse functions in immune modulation.
In line with its immune repression function, an evolutio-
narily well-conserved immunosuppressive domain has
been identified in its first transmembrane helix located at
the LALLFWL sequence [64]. Regulation of type I Jak-
STAT IFN pathway by LMP1 may represent an evolved
strategy for EBV to balance the complexity of EBV/host
interaction for its long-term persistence.
Apoptosis plays an important role in viral innate
immune responses [73]. LMP1 is a well known anti-
apoptotic protein which induces some anti-apoptotic
proteins such as Survivin, A20, and Bcl-2 (Figure 2).
Besides its immune modulation role in latency, LMP1
is upregulated in hairy leukoplakia, the only pathologic
manifestation of permissive EBV replication, possibly
providing survival and immune evasion signals [74].
For a comprehensive understanding of the immune mod-
ulation functions of LMP1, see the excellent review [64].
EBERs
As stated above, EBERs can orchestrate immune
responses mediated by TLR3 or RIG-I and induces
inflammatory cytokines and type I IFNs. EBERs-induced
type I IFNs can trigger apoptosis in EBV-infected cells
[31], and helps the infected cells prevent from superinfec-
tion. But EBERs do not confer IFN resistance [75]. EBV
has developed strategies to counteract this IFN-induced
apoptosis. First, EBERs themselves binds to PKR in vitro,
a key mediator of the antiviral effect of IFNs, and inhibit
PKR- or IFNa-mediated apoptosis [31] (Figure 2),
although in BL cells, EBER inhibition of PKR-mediated
apoptosis is likely not accomplished by direct inhibition
of PKR [76]. Second, BHRF1, a homolog of cellular Bcl-2,
blocks apoptosis by binding to a limited amount of Bim
[77] (Figure 2). Third, as stated above, LMP1 induces
expression of anti-apoptosis proteins. In addition,
EBNA2 is resistant to IFN-induced anti-proliferation by
reducing or abolishing expression of selected ISGs
including ISG54, PKR, OAS, and IFI6-16 [78].
EBV-encoded miRNAs
EBV encodes at least 25 miRNAs [79]. These miRNAs
are encoded by two transcripts, one set in intronic
regions of the BamH I-A rightward transcript (BART)
gene and the other set maps to the 5’-UTR (BHRF1-1
miRNA) and 3-UTR (BHRF1-2, 1-3 miRNAs) of the
BHRF gene. The three BHRF1 miRNAs are expressed
during type 3 latency while the large cluster of BART
miRNAs (22 miRNAs) are expressed during type 2
latency [80]. With the exception of miR-BART2, all of
the BART-derived miRNAs are mapped to two clusters.
BART2 miRNA is highly expressed in primary BL (type
1) and primary effusion lymphomas (PEL). The func-
tions of these miRNAs are largely unknown [81,82], but
recently their important roles in EBV pathogenesis and
oncogenesis have been increasingly recognized. BART5
miRNA targets PUMA, a pro-apoptotic factor of the
Bcl2 family, and therefore promotes host cell survival
[83]. BART2 miRNA targets the EBV DNA polymerase
BALF5 for degradation, and therefore effectively inhibits
lytic replication [84]. BHRF1-3 miRNA represses expres-
sion of CXCL11 [81].
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miR-155 is produced from B cell intergration cluster
(BIC) transcript, and is a novel crucial regulator of
innate immunity, and it is also an important oncogenic
miRNA (oncomiR) that is implicated in various lym-
phoid malignancies. miR-155 targets SHIP1 [85], IKKε
[86], Table 2 [87], SOCS1 [88], and MyD88 [89], all of
which are important intermediates of innate immune
signaling pathways. SHIP1, IKKε, and SOCS1 also play
roles in cancers. We have evidence showing that miR-
155 also targets SHIP1 in the EBV context (data to be
published). In addition, miR-155 targets FOXO3a, and
therefore plays an important role in breast cancers [90].
Unlike KSHV which encodes a viral ortholog of miR-
155 [91,92], EBV does not encode miR-155 ortholog but
induces expression of cellular miR-155 by LMP1 signal-
ing through NFkappaB and AP1 [93-95]. We have evi-
dence showing that BIC transcript is also induced by
IRF4 in EBV latency as well as in human T-cell leuke-
mia virus 1 (HTLV1)-infected cells, and the levels of
BIC and IRF4 are correlated in HTLV1-associated adult
T cell leukemia/lymphoma (ATLL) tumors (data to be
published).
In addition, EBV induces miR-146, miR-21, miR-23a,
miR-24, miR-27a, and miR-34a in its latency [96-98].
Like miR-155, both miR-146 and miR-21 are also onco-
genic and are important regulators of innate immune
responses. miR-146 targets TRAF6, IRAK1 and -2, and
therefore attenuates type I IFN production in macro-
phages [99]. miR-21 targets the proinflammatory tumor
suppressor PDCD4 and therefore promotes cell transfor-
mation and negatively regulates TLR4 signaling
[100,101].
EBNA2
EBNA2 has resistance to type I IFNs by reducing or
abolishing expression of four ISGs: ISG54, PKR, OAS,
and IFI6-16 [78]. However, EBNA2 can stimulate IFNb
expression and ISGF3 activity in BL cell lines [102].
LMP2A and 2B
LMP2A and -2B limit IFN signaling by promoting turn-
over of both type I and II IFN receptors, IFNAR and
IFNGR [103].
Evasion of IRF7-mediated IFN responses in latency
EBV type 3 latency expresses a few more proteins than
other latency programs, and mainly exists in immuno-
compromised hosts in vivo and lymphoblastoid cell lines
in vitro. This latency is associated with distinct lympho-
proliferative diseases in patients infected with HIV or
suffering from other immunodeficiency conditions, such
as iatrogenic immunodeficiency following solid organ
transplantation. Latency 3 also exists in healthy people
[104], presumably as the transition process to the desti-
nation “true latency”.
LMP1 is expressed at a much higher level in latency 3
compared with other latency programs. We have shown
ample evidence that LMP1 in latency 3 induces as well
as activates IRF7 [105-107], the “master” regulator of
type I IFN responses [108]. However, activated IRF7
d o e sn o ti n d u c ec o n s i d e r a b l et y p eII F N si nE B V
latency. The mechanism underlying this paradox is
unclear. Understanding how EBV escapes the IRF7/IFN
signaling pathway but retains IRF7’s oncogenic activity
is of great interest, as their outcomes shape not only the
immune response to viral infection, but also affect
aspects of host cell proliferation and survival. Recently,
another IRF7 splicing variant, IRF7C, which is also
induced by LMP1, has been identified to inhibit IRF7
transcriptional activity by competing with IRF7 for bind-
ing to IFN promoters [109]. This may provide a valuable
clue for escape of IRF7-mediated IFN signaling in EBV
latency. We are performing genome-wide screening to
identify regulators of the IRF7/IFN signaling in EBV
latency.
Immune evasion in lytic cycle
EBV GPCR
A systematic screen of EBV lytic genes has identified
BILF1, the EBV G protein-coupled receptor (GPCR)
homolog which has constitutive signaling functions, as a
specific inhibitor for MHC class I presentation on cell
surface [110]. BILF1 targets MHC class I molecules for
lysosomal degradation, and therefore abrogates its
recognition by immune T cells (Figure 2). However,
BILF1 exerts this effect through direct interaction with
MHC class I complexes, independently of its GPCR sig-
naling, and the underlying mechanism is distinct from
those of other viral proteins which target MHC class I
for degradation [110]. BILF1 also constitutively inhibits
PKR phosphorylation [111,112]. KSHV GPCR homolog
(ORF74) does not have this function, whereas the BILF1
homolog of the Rhesus g1-herpesvirus CeHV15 has simi-
lar function with EBV BILF1 in downregulation of MHC
class I [110].
BGLF5 and BNLF2a
Two other EBV proteins have been described which sig-
nificantly suppress adaptive immune responses. BGLF5,
the EBV alkaline exonuclease (DNase), helps EBV to
escape host T-cell recognition and elimination of the
infected cell by shutting off the expression of MHC
class I and II genes [113]. BNLF2a, an EBV lytic cycle
early protein, blocks MHC class I presentation through
inactivation of the TAP1/TAP2 peptide transporter to
impair CD8
+ T-cell response [114,115] (Figure 2).
BZLF1 and BRLF1
The IE transcription factor BZLF1 is homologous to
HSV1 ICP0 and host AP1. Like HSV1 ICP0 and EBV
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cally inhibits IFNg signaling at multiple levels: BZLF1
inhibits IFNg-stimulated STAT1 Tyr701 phosphorylation
as well as tyrosine phosphorylation of Jak1 and Jak2,
decreases expression of IFNgRa,a n dr e d u c e sI F N g-
induced MHC II expression [117]. BZLF1 interacts with
P53 and inhibits transcription of both proteins. BZLF1
also targets P53 protein for degradation through
MDM2-independent ubiquitination pathway [118] (Fig-
ure 2). In addition, as a transcription factor, BZLF1 inhi-
bits TNFR1 expression through direct interaction with
C/EBP proteins [119].
We have shown that BZLF1 inhibits IRF7 transcrip-
tional activity [120]. BZLF1 and IRF7 physically interact.
But BZLF1 had no effect on IRF7 nuclear translocation.
The exact mechanism remains further study.
The other IE protein, BRLF1, decreases expression of
IRF3 and -7, and therefore negatively regulates IFN
responses to facilitate viral replication [121] (Figure 2).
BGLF4
BGLF4, the only EBV protein kinase (PK) whose ortho-
log UL13 in HSV1 has been implicated in counteracting
IFN production [122], was identified as an IRF3-inter-
acting protein in yeast two-hybrid screening [123].
BGLF4 phosphorylates IRF3 in vitro and does not pre-
vent IRF3 dimerization and nuclear translocation. Phos-
phorylation of IRF3 by BGLF4 did not result in its
proteasomal degradation, instead, diminished IRF3 bind-
ing to DNA, probably through affecting IRF3 optimal
conformation for stable DNA binding [123] (Figure 2).
BGLF4 also inhibits STAT1 Tyr701 phosphorylation
[123] (Figure 2).
BILF4
Screening of EBV ORF library has identified BILF4
(LF2), which is also expressed at IE stage, as a potent
inhibitor for IRF7-stimulated IFN promoter activity
[26]. This inhibition effect is specific to IRF7 but not to
IRF3. BILF4 is located in the nucleus and does not inhi-
bit IRF7 phosphorylation and nuclear translocation;
instead, it interrupts IRF7 dimerization through interac-
tion with IRF7 central IRF association domain (IAD)
[26]. Rhesus lymphocryptovirus LF ortholog has similar
function with EBV LF2 [26]. LF2 is not necessary for
EBV replication; in fact, it inhibits EBV replication
[124].
BARF1
EBV-encoded BARF1 functions as a colony-stimulating
factor 1 (CSF1) receptor for human CSF1, which is
known to induce proliferation of bone marrow macro-
phages and promotes mononuclear cells to release cyto-
kines such as type I IFNs, TNFa, and IL1 [125].
BSMLF1
BSMLF1 is known as SM, BMLF1, EB2 and Mta.
BSMLF1 is a transactivator and mRNA export factor
that is essential for EBV replication. BSMLF1 binds to
and inhibits PKR activation, and also interacts with
TAP, CRM1, and PML-NB P110b subunit [126].
GP42
The envelope glycoprotein, GP42 which is encoded by
BZLF2, binds to MHC class II and mediates viral entry
to B cells. Binding of GP42 to MHC class II subverts
CD4
+ T cell activation through disruption of the inter-
action between MHC class II and T cell receptor (TCR)
[14] (Figure 2).
Perspectives
It is clear that modulation of the host innate immune
r e s p o n s e si sak e yc o m p o n e n ti nE B Vl i f e c y c l e .E B V ,
compared with other herpesviruses, encodes more
sophisticated and successful strategies for this purpose.
EBV encodes fewer products to accomplish this goal
and successfully infects more than 90% of the popula-
tion. This topic had not been taken into account until
recently, emerging evidence show that EBV noncoding
R N A s ,I Et r a n s a c t i v a t o r s ,E B N A 1 ,a n dL M P 1 ,p l a y
important roles in these processes. However, these lim-
ited pieces of evidence are far away from clear to eluci-
date the whole picture of how EBV subverts host innate
immune system. The study of EBV-noncoding RNAs
and miRNAs in modulation of innate immune
responses is just beginning, and will be the focus of this
topic in the near future. How innate immune signaling
pathways such as TLR and RLR signaling pathways
respond to EBV primary infection is not clear, although
this is the key to understand how the virus establishes
latency after primary infection. Whether the innate
immune signaling manipulates EBV reactivation is also
an interesting question. Understanding the mechanisms
whereby EBV evades innate immune responses to estab-
lish long-life latency and to develop malignancies is
paramount for therapeutics of EBV-associated
malignancies.
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